BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007).

Reports on the relationship between leptin and physical activity (PA) at the population level are scarce.

The present study examined the relationship between serum leptin concentrations and PA in a nationally representative sample of 3001 Iranian adults aged 25 to 64 years.

Serum leptin was measured with an enzyme-linked immunosorbent assay.

After adjustment for age, area of residence, smoking, body mass index, and waist circumference, total PA (r = -0.129, P = .038 in men and r = -0.226, P = .006 in women), the duration of vigorous-intensity activity (r = -0.120, P = .044 in men and r = -0.154, P = .019 in women), the duration of moderate-intensity activity (r = -0.114, P = .047 in men and r = -0.160, P = .018 in women), and time spent on sedentary behaviors (r = 0.194, P = .014 in men and r = -0.204, P = .007 in women) were significantly correlated with serum leptin.

In both sexes, participants in higher categories of PA had significantly lower serum leptin levels.

In conclusion, our results demonstrated an inverse association between leptin concentrations and PA independent of age, sex, smoking, and body adiposity.

Our results point to the regulatory effects of PA on serum leptin.

[MeSH-major] Exercise. Leptin / blood. Obesity / physiopathology. Population Surveillance

Genetic Alliance. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.

MedlinePlus Health Information. consumer health - Obesity.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.

(PMID = 20580780.001).

[ISSN] 1532-8600

[Journal-full-title] Metabolism: clinical and experimental

[ISO-abbreviation] Metab. Clin. Exp.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Leptin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of serum adipokine levels in colorectal cancer patients.

BACKGROUND: Adipokines may significantly influence the growth and proliferation of tumor stroma and malignant cells within.

Reduced adiponectin and increased leptin serum levels were found in colorectal cancer (CRC) patients.

Recently, it has been demonstrated that tumor necrosis factor-alpha (TNF-alpha) is able to induce dose-dependent changes in serum adipokine levels.

MATERIALS AND METHODS: Baseline leptin, adiponectin and TNF-alpha levels were analyzed in 90 patients with histologically diagnosed primary or newly diagnosed metastatic CRC treated at 'Tor Vergata' Clinical Center and followed up for a median period of 3 years.

RESULTS: Serum leptin levels were higher in CRC patients than in controls (p<0.0001).

Conversely, serum adiponectin levels were lower in CRC patients than in controls (p<0.0001).

Leptin inversely correlated with adiponectin (p<0.005).

The leptin/adiponectin (L/A) ratio was eight-fold greater in CRC compared to controls (p<0.0001).

CONCLUSION: Serum adipokine levels might have a role in the biology of CRC and the combined measurement of leptin and adiponectin levels might provide useful prognostic information in the management of patients with CRC.

[MeSH-minor] Adiponectin / blood. Adult. Aged. Case-Control Studies. Female. Follow-Up Studies. Humans. Leptin / blood. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Survival Rate. Treatment Outcome. Tumor Necrosis Factor-alpha / blood

Genetic Alliance. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - Liver Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19661351.001).

[ISSN] 1791-7530

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Relationship between serum concentrations of leptin, soluble leptin receptor, testosterone and IGF-I, and growth during the first year of postnatal life in the male rhesus monkey, Macaca mulatta.

OBJECTIVES: Subnormal leptin levels in low birth weight infants may allow for catch-up growth during infancy.

Scant data are available that relate growth with circulating leptin during normal infancy in primates.

The current study objective was to examine the association between serum leptin, its soluble receptor (sOB-R), testosterone and IGF-I concentrations, and body weight during infancy in male rhesus monkeys.

DESIGN: Hormone levels were assessed longitudinally in animals (n = 7) from birth until 1 year of age.

RESULTS: Body weight increased during the first 6 months of life and was strongly correlated with rising IGF-I levels and, as IGF-I plateaued and then declined during the second half of the year, body weight gain decelerated.

In contrast, leptin levels declined gradually with age during the first year of life in conjunction with increasing body weight.

There was no association between body weight gain and serum leptin levels or between serum testosterone and leptin values.

Since sOB-R levels also declined with leptin values, it does not appear that levels of bioavailable leptin changed during infancy.

CONCLUSIONS: The data do not support the contention that leptin regulates growth during infancy, but the close association between IGF-I levels and body weight suggested that this hormone may regulate growth in infant male monkeys.

The failure to observe an association between serum testosterone and leptin concentrations suggested that leptin is not involved in the activation of the hypothalamic-pituitary -testicular axis during this developmental period.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. TESTOSTERONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15994757.001).

[ISSN] 0804-4643

[Journal-full-title] European journal of endocrinology

[ISO-abbreviation] Eur. J. Endocrinol.

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / GM08248; United States / NICHD NIH HHS / HD / HD08610; United States / NICHD NIH HHS / HD / HD13254; United States / NICHD NIH HHS / HD / HD41749; United States / NCRR NIH HHS / RR / RR03024

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 3XMK78S47O / Testosterone; 67763-96-6 / Insulin-Like Growth Factor I

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] B-cell cutaneous lymphoid hyperplasia representing progressive transformation of germinal center: a report of 2 cases.

The authors report histomorphologic, immunophenotypic, and genotypic findings of 2 cases of B-cell CLH demonstrating progressive transformation of germinal center (PTGC).

PTGC was characterized by enlarged but well-circumscribed follicles without clear demarcation of the germinal center and mantle zone, which contained a predominance of small lymphocytes and variable numbers of centrocytes, centroblasts, and immunoblasts.

However, there were no centroblasts and immunoblasts resembling lymphocytic and/or histiocytic Reed-Sternberg cell variants in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in either lesion.

These unusual CLHs should be differentiated from the primary cutaneous marginal zone B-cell lymphoma, primary cutaneous follicular lymphoma, particularly "floral variant," or NLPHL.

To avoid overdiagnosis and overtreatment, immunophenotypic and genotypic studies are required along with careful morphologic examination.

[MeSH-major] B-Lymphocytes / pathology. Cell Transformation, Neoplastic / pathology. Germinal Center / pathology. Pseudolymphoma / pathology. Skin Diseases / pathology

[MeSH-minor] Aged. Biomarkers / metabolism. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. Humans. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, Follicular / diagnosis. Male. Middle Aged. Skin Neoplasms / diagnosis

MedlinePlus Health Information. consumer health - Skin Conditions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18815203.001).

[ISSN] 1940-2465

[Journal-full-title] International journal of surgical pathology

[ISO-abbreviation] Int. J. Surg. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms.

Here, we examined DBC1 at 9q33.1 as a potential target in lymphomagenesis.

DBC1 is a putative tumor suppressor that has been shown to be involved in the regulation of cell growth and programmed cell death.

DBC1 was hypermethylated in 5 of 5 B-cell-derived lymphoma cell lines, 41 of 42 diffuse large B-cell lymphomas, 24 of 24 follicular lymphomas, 5 of 5 mantle cell lymphomas, 4 of 4 small lymphocytic lymphomas, 1 of 2 lymphoplasmacytoid lymphomas, and in 12 of 12 acute lymphoblastic leukemias, but was unmethylated in 1 case of splenic marginal zone lymphoma, in 12 of 12 multiple myelomas, in 24 of 24 reactive lymph nodes, and in 12 of 12 samples of blood lymphocytes from random donors.

DBC1 hypermethylation was associated with transcriptional silencing in lymphoma cell lines, and reexpression of this gene could be induced by treatment with the demethylating agent, 5-aza-2'-deoxycytidine.

Our data suggest that hypermethylation of the DBC1 promoter region is a frequent event during the development of lymphoproliferative malignancies, and that DBC1 hypermethylation may serve as a marker for these cancers.

[MeSH-minor] Aged. CpG Islands / genetics. DNA, Neoplasm / genetics. Humans. Middle Aged. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18264085.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DBC1 protein, human; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The effects of six-week oral administration of the newly synthesized substance B496 (methyl-4-[2-[2-hydroxy-3-(4-ethylcarbamoyl)phenoxyprophyl]amino]etyl)-phenoxyacetate hydrochloride) on serum glucose, triglycerides, total cholesterol, and leptin levels were studied in male Wistar rats fed with a high-fat diet.

The results indicated a significant reduction in serum glucose levels (-26 %, p<0,01), triacylglyceride levels (-21 %, p<0,05) and leptin levels (-43 %, p<0,01).

Further the effect of a single intraperitoneal dose (1 mg/kg) of B496 and BRL-37344 on serum leptin levels in the C57Bl/6J mouse was investigated.

Administration of BRL-37344 resulted in a significant decrease in serum leptin levels (-55 %, p<0,001).

[MeSH-major] Adrenergic beta-Agonists / pharmacology. Leptin / blood. Receptors, Adrenergic, beta-3 / drug effects

Hazardous Substances Data Bank. CHOLESTEROL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16838489.001).

[ISSN] 1210-7816

[Journal-full-title] Ceská a Slovenská farmacie : casopis Ceské farmaceutické spolecnosti a Slovenské farmaceutické spolecnosti

[ISO-abbreviation] Ceska Slov Farm

[Language] cze

[Publication-type] English Abstract; Journal Article

[Publication-country] Czech Republic

[Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / B496 compound; 0 / Blood Glucose; 0 / Ethanolamines; 0 / Leptin; 0 / Phenoxyacetates; 0 / Receptors, Adrenergic, beta-3; 0 / Triglycerides; 114333-71-0 / BRL 37344; 97C5T2UQ7J / Cholesterol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus.

A patient with chronic hepatitis C virus (HCV) presented to our clinic with a hepatic mass as well as lymphocytosis.

Biopsy of the hepatic mass revealed apposed hepatocellular carcinoma (HCC) and small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL).

Dramatic examples of lymphoma regression during treatment with antiviral medication in chronic HCV patients have suggested an etiologic role for HCV in lymphomagenesis.

A growing body of research seeks to clarify the details of the interaction between HCV and B-cell lymphomas.

This case of adjacent SLL/CLL and HCC is the first published diagnosis of these two diseases in the liver at one time, and the only published example of the physical apposition of any lymphoma and HCC.

[MeSH-major] Carcinoma, Hepatocellular / virology. Leukemia, Lymphocytic, Chronic, B-Cell / virology. Liver Neoplasms / virology

[MeSH-minor] Aged. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / diagnosis. Humans. Male

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

Genetic Alliance. consumer health - Hepatitis.

MedlinePlus Health Information. consumer health - Liver Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 S. Karger AG, Basel.

(PMID = 20029171.001).

[ISSN] 1421-9662

[Journal-full-title] Acta haematologica

[ISO-abbreviation] Acta Haematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Switzerland

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells.

However, the interaction between malignant B and T cells remains to be fully elucidated.

In a previous study, we have reported that ligation of CCL19-CCR7 and CXCL13-CXCR5 activates paternally expressed gene 10 (PEG10), resulting in an enhancement of apoptotic resistance in B-cell acute lymphocytic leukemia (B-ALL) CD23+CD5+ B cells.

Here, we report that B-ALL CD23+CD5+ B cells produce IL-10 at high level, which can be further elevated by costimulation with CCL19 and CXCL13.

CCL19/CXCL13-activated B-ALL CD23+CD5+ B cells, in turn, increase IL-10 expression in syngeneic CD8+ T cells in a B cell-derived IL-10-dependent manner and requiring a cell-cell contact.

Moreover, using a short hairpin RNA to knockdown PEG10, we provide direct evidence that increased expression of PEG10 in B-ALL CD23+CD5+ B cells is involved in malignant B-T cell interaction, contributing to the up-regulation of IL-10 expression, as well as to the impairment of cytotoxicity of syngeneic CD8+ T cells.

Thus, malignant B-ALL CD23+CD5+ B cells play an immunoregulatory role in controlling different inflammatory cytokine expressions.

[MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / immunology. CD8-Positive T-Lymphocytes / immunology. Chemokine CCL19 / physiology. Chemokine CXCL13 / physiology. Immunologic Surveillance / immunology

[MeSH-minor] Adolescent. Adult. Antigens, CD5 / analysis. Child. Child, Preschool. Cytotoxicity, Immunologic. Female. Humans. Interleukin-10 / metabolism. Male. Middle Aged. Proteins / antagonists & inhibitors. Proteins / genetics. Proteins / metabolism. RNA, Small Interfering / pharmacology. Receptors, IgE / analysis. Up-Regulation

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] J Immunol. 2007 Nov 15;179(10):7184

(PMID = 17709502.001).

[ISSN] 0022-1767

[Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)

[ISO-abbreviation] J. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD5; 0 / CXCL13 protein, human; 0 / Chemokine CCL19; 0 / Chemokine CXCL13; 0 / PEG10 protein, human; 0 / Proteins; 0 / RNA, Small Interfering; 0 / Receptors, IgE; 130068-27-8 / Interleukin-10

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Inherited predisposition to chronic lymphocytic leukemia.

Inherited susceptibility to chronic lymphocytic leukemia (CLL) has been recognized for decades.

Approximately 10% of individuals with CLL report a family history of CLL or a related lymphoproliferative disorder, and genetic predisposition is the best understood risk factor for CLL.

Monoclonal B-cell lymphocytosis (MBL) has been identified recently as a likely precursor to CLL; it is found in the general population with increasing age and enriched in unaffected relatives of individuals with familial CLL.

Studies of MBL as well as mouse models of CLL may lead to better understanding of early CLL pathogenesis that is relevant to familial predisposition.

To date, the identification of genes that predispose to familial CLL has been slow, primarily due to the relatively few families available for study, the small size of those families and disease causation most likely by multiple genes that each confer smaller risks.

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]

[Cites] Leukemia. 2002 Jul;16(7):1229-32 [12094247.001]

[Cites] Leuk Res. 2002 Sep;26(9):791-4 [12127552.001]

[Cites] Blood. 2002 Aug 1;100(3):1100-1 [12150154.001]

[Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]

[Cites] Br J Haematol. 1997 Apr;97(1):107-12 [9136948.001]

[Cites] Immunity. 1997 Nov;7(5):703-13 [9390693.001]

[Cites] Leukemia. 1998 Nov;12(11):1696-8 [9823943.001]

[Cites] Am J Hum Genet. 1999 Jul;65(1):265-9 [10364544.001]

[Cites] Leukemia. 1999 Oct;13(10):1497-500 [10516748.001]

[Cites] Nat Rev Genet. 2005 Oct;6(10):756-65 [16205715.001]

[Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]

[Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]

[Cites] Int J Immunogenet. 2006 Feb;33(1):21-4 [16426238.001]

[Cites] Leukemia. 2006 Feb;20(2):280-5 [16341048.001]

[Cites] Cytometry B Clin Cytom. 2007 Sep;72(5):344-53 [17266153.001]

[Cites] Cytogenet Genome Res. 2007;118(1):8-12 [17901694.001]

[Cites] Int J Cancer. 2007 Nov 15;121(10):2260-6 [17583571.001]

[Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]

[Cites] Nat Genet. 2007 Nov;39(11):1315-7 [17934461.001]

[Cites] Br J Haematol. 2007 Dec;139(5):690-700 [18021083.001]

[Cites] Br J Haematol. 2007 Dec;139(5):701-8 [18021084.001]

[Cites] Br J Haematol. 2007 Dec;139(5):724-9 [18021087.001]

[Cites] Br J Haematol. 2007 Dec;139(5):762-71 [18021089.001]

[Cites] Br J Haematol. 2007 Dec;139(5):774-9 [18021091.001]

[Cites] Br J Haematol. 2007 Dec;139(5):645-57 [17941951.001]

[Cites] Br J Haematol. 2007 Dec;139(5):809-19 [17941952.001]

[Cites] Br J Haematol. 2007 Dec;139(5):744-52 [17961188.001]

[Cites] J Clin Oncol. 2007 Dec 1;25(34):5448-57 [17968022.001]

[Cites] Nat Genet. 2008 Mar;40(3):281-3 [18264098.001]

[Cites] Nat Genet. 2008 May;40(5):631-7 [18372901.001]

[Cites] Nat Genet. 2008 May;40(5):623-30 [18372905.001]

[Cites] Nat Genet. 2008 May;40(5):616-22 [18385676.001]

[Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]

[Cites] Blood. 2008 Jun 15;111(12):5691-3 [18424666.001]

[Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]

[Cites] Leuk Res. 2009 Jan;33(1):162-5 [18556064.001]

[Cites] Br J Haematol. 1999 Dec;107(3):616-24 [10583268.001]

[Cites] Blood. 2000 Feb 15;95(4):1413-9 [10666219.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3028-33 [10716693.001]

[Cites] Eur J Haematol. 2000 Aug;65(2):114-7 [10966171.001]

[Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]

[Cites] Blood. 2000 Dec 1;96(12):3982-4 [11090088.001]

[Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]

[Cites] Blood. 2001 Apr 1;97(7):2098-104 [11264177.001]

[Cites] Int J Cancer. 2001 Apr 15;92(2):203-7 [11291046.001]

[Cites] Cancer. 2001 Sep 1;92(5):1325-30 [11571749.001]

[Cites] Leuk Lymphoma. 2001 Jun;42(1-2):99-108 [11699227.001]

[Cites] Lancet. 2002 Mar 30;359(9312):1114-9 [11943260.001]

[Cites] Blood. 2002 Jun 1;99(11):4216-8 [12010828.001]

[Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60 [12011454.001]

[Cites] Blood. 2002 Jul 15;100(2):603-9 [12091354.001]

[Cites] Br J Haematol. 2002 Dec;119(3):713-5 [12437649.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]

[Cites] Cancer Causes Control. 2002 Nov;13(9):791-5 [12462543.001]

[Cites] Leuk Lymphoma. 2002 Oct;43(10):1987-90 [12481897.001]

[Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]

[Cites] Br J Haematol. 2003 Jun;121(6):866-73 [12786797.001]

[Cites] Leuk Res. 2003 Oct;27(10):973-5 [12860021.001]

[Cites] Blood. 2004 Mar 15;103(6):2337-42 [14630808.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2424-33 [15059895.001]

[Cites] J Natl Cancer Inst. 2004 May 5;96(9):673-82 [15126604.001]

[Cites] Leukemia. 2004 Jun;18(6):1162-3 [15085160.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1065-7 [15184265.001]

[Cites] Semin Hematol. 2004 Jul;41(3):201-6 [15269880.001]

[Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]

[Cites] Cancer Cell. 2004 Oct;6(4):399-408 [15488762.001]

[Cites] N Engl J Med. 1987 May 21;316(21):1289-94 [3574400.001]

[Cites] Leuk Res. 1991;15(5):305-14 [2046383.001]

[Cites] Cancer Res. 1992 Jan 15;52(2):437-43 [1370214.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12530-4 [7809072.001]

[Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]

[Cites] Am J Hum Genet. 1996 Nov;59(5):990-8 [8900225.001]

[Cites] Leuk Res. 2005 Jan;29(1):59-61 [15541476.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16600-5 [15545599.001]

[Cites] N Engl J Med. 2005 Apr 21;352(16):1667-76 [15843669.001]

[Cites] Cancer. 2005 May 1;103(9):1906-15 [15779016.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1245-50 [15894680.001]

[Cites] Leukemia. 2005 Jun;19(6):1025-8 [15800670.001]

[Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1088-9; author reply 1093-5 [16030308.001]

[Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1089-90; author reply 1093-5 [16030309.001]

[Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1090-1; author reply 1093-5 [16030310.001]

[Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1091-2; author reply 1093-5 [16030311.001]

[Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1092-3; author reply 1093-5 [16030312.001]

[Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]

[Cites] Am J Hum Genet. 2005 Sep;77(3):420-9 [16080117.001]

[Cites] J Immunol. 2005 Oct 1;175(7):4309-19 [16177071.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]

[Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1466-74 [16204696.001]

[Cites] Int J Cancer. 2006 Apr 1;118(7):1831-5 [16217763.001]

[Cites] J Clin Oncol. 2006 Feb 20;24(6):983-7 [16432079.001]

[Cites] Br J Haematol. 2006 Apr;133(1):59-61 [16512829.001]

[Cites] Leukemia. 2006 Apr;20(4):728-9 [16437141.001]

[Cites] Semin Oncol. 2006 Apr;33(2):195-201 [16616066.001]

[Cites] Nat Genet. 2006 Jun;38(6):659-62 [16715099.001]

[Cites] Blood. 2006 Jul 15;108(2):638-44 [16574953.001]

[Cites] Haematologica. 2006 Aug;91(8):1117-20 [16885053.001]

[Cites] Blood. 2006 Aug 15;108(4):1334-8 [16670263.001]

[Cites] Leuk Res. 2006 Dec;30(12):1573-6 [16581122.001]

[Cites] Blood. 2007 Feb 1;109(3):916-25 [17047154.001]

[Cites] Blood. 2007 Feb 1;109(3):1202-10 [17053054.001]

[Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]

[Cites] Br J Haematol. 2007 Apr;137(2):173-5 [17391501.001]

[Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]

[Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]

[Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]

[Cites] Blood. 2007 Jun 15;109(12):5079-86 [17351108.001]

[Cites] Leuk Lymphoma. 2007 Jun;48(6):1087-91 [17577771.001]

[Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]

[Cites] Nat Genet. 2007 Aug;39(8):977-83 [17603485.001]

[Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]

(PMID = 19802369.001).

[ISSN] 1747-4094

[Journal-full-title] Expert review of hematology

[ISO-abbreviation] Expert Rev Hematol

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / K23 CA115682-03; United States / NCI NIH HHS / CA / K23 CA115682-04; None / None / / K23 CA115682-03; United States / NCI NIH HHS / CA / CA115682-01; United States / NCI NIH HHS / CA / K23 CA115682; United States / NCI NIH HHS / CA / CA115682-04; United States / NCI NIH HHS / CA / K23 CA115682-01; United States / NCI NIH HHS / CA / CA115682-02; United States / NCI NIH HHS / CA / K23 CA115682-02

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases

[Keywords] NOTNLM ; association / familial chronic lymphocytic leukemia / linkage / lymphocytosis / monoclonal B cell

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum leptin levels in acute myocardial infarction.

BACKGROUND: Several studies have shown an association of serum leptin levels with cardiovascular diseases.

The present study was undertaken to assess levels of serum leptin in patients presenting with acute ST segment elevation myocardial infarction.

The serum leptin levels in patients with myocardial infarction was 6.51 +/- 6.76 ng/ml versus 2.86 +/- 2.22 ng/ml in controls.

In the multivariate analysis the odds ratio for serum leptin with myocardial infarction was 1.45 with a 95% confidence interval of 1.2 to 1.8.

CONCLUSIONS: Our results suggest that serum leptin level is elevated in patients with acute ST segment elevation myocardial infarction.

[MeSH-major] Leptin / blood. Myocardial Infarction / blood

MedlinePlus Health Information. consumer health - Heart Attack.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15852893.001).

[ISSN] 0019-4832

[Journal-full-title] Indian heart journal

[ISO-abbreviation] Indian Heart J

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Leptin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.

The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL).

Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m(2) on day 1 and cladribine 0.1 mg/kg subcutaneously on days 2-6.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. CLADRIBINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20578816.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Equilibrative Nucleoside Transporter 1; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / SLC29A1 protein, human; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].

OBJECTIVE: To investigate the clinical and pathological features of non-Hodgkin's lymphoma (NHL) and to evaluate the applicability of the new WHO classification of lymphoid neoplasms.

METHODS: According to the new WHO classification, a total of 500 cases of non-Hodgkin's lymphoma diagnosed during the period 1992 - 2003 were reviewed and reappraised with their morphological, immunological and clinical characteristics.

RESULTS: Among 500 cases previously diagnosed as lymphomas, 493 cases (98.6%) were confirmed to be NHL, of which B-cell neoplasms was 69.0% and T/NK-cell neoplasms 29.8%.

Overall, 6 subtypes including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), unspecified peripheral T-cell lymphoma (PT-un), precursor T-lymphoblastic lymphoma (T-LBL), extranodal marginal zone B-cell lymphoma of MALT type (MALT) and B-small lymphocytic lymphoma (B-SLL) were among the most common subtypes.

In pediatric and young patient populations, the most common subtypes were LBL, DLBCL and Burkitt's lymphoma.

Marginal zone B-cell lymphoma and SLL demonstrated the best prognosis, LBL and PT-un both the worst, whereas DLBCL and FL had an intermediate prognosis, however, subgrouping of FL according to WHO classification did not reveal a significant survival difference (P > 0.05).

CONCLUSIONS: Basing upon the results of a comprehensive survey on the morphologic features, immunophenotyping and clinical data of the above cases, the new WHO classification of lymphoid neoplasms is practical and easily applicable for routine pathological evaluation of lymphoproliferaive disorders and in guiding the clinical management.

[MeSH-major] Lymphoma, Non-Hodgkin / classification

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. China / epidemiology. Female. Humans. Killer Cells, Natural. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / classification. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. World Health Organization

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15796877.001).

[ISSN] 0529-5807

[Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology

[ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition.

BACKGROUND: The relationship between thyroid status, including subclinical hypothyroidism (SH) and serum leptin is controversial or uncertain.

Therefore we evaluated serum leptin in SH and overt hypothyroidism (OH) and determined the effects of levothyroxine (LT(4)) replacement on serum leptin in these disorders.

METHODS: Serum leptin, thyrotropin (TSH), free thyroxine, insulin, glucose, and body composition parameters were compared in 55 SH, 20 OH, and 28 euthyroid (EU) pre- and postmenopausal women.

In addition, the effect of LT(4) treatment on serum leptin in SH and OH was assessed.

RESULTS: The mean +/- SD (median) serum leptin concentrations in the OH and SH groups were higher than in the EU group (35.1 +/- 27.2 [33.0] and 36.6 +/- 21.9 [30.6] ng/mL, respectively, vs. 23.2 +/- 19.3 [17.9] ng/mL, p = 0.011), but the difference was only significant in postmenopausal women.

In premenopausal women there was no correlation between leptin, BMI, or FMI and serum TSH levels (r(s) = 0.009, p = 0.474; r(s) = 0.043, p = 0.367; r(s) = 0.092, p = 0.232).

In the postmenopausal women, the partial correlation coefficient between TSH and leptin was present, even when controlling for BMI (r(s) = 0.297, p = 0.042) and FMI (r(s) = 0.275, p = 0.050).

LT(4) treatment was associated with a reduction of serum leptin concentrations in the OH group (p = 0.008).

In SH group there were no differences between LT(4) replacement or no treatment, since a fall in serum leptin levels was detected in both SH subgroups, despite a more pronounced fall with LT(4) use.

CONCLUSIONS: Serum leptin concentrations are elevated in postmenopausal women with SH or OH.

A relationship between thyroid status and serum leptin is further supported by the fact that LT(4) treatment, to restore the EU status, reduced serum leptin levels in OH in the absence of significant effects on BMI.

In women, hypothyroidism influences either leptin secretion or degradation and this effect is more pronounced in postmenopausal than in premenopausal women.

[MeSH-major] Body Composition. Hormone Replacement Therapy. Hypothyroidism / drug therapy. Leptin / blood. Postmenopause / blood. Premenopause / blood. Thyroxine / therapeutic use

MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

MedlinePlus Health Information. consumer health - Hypothyroidism.

Hazardous Substances Data Bank. LEVOTHYROXINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19415994.001).

[ISSN] 1557-9077

[Journal-full-title] Thyroid : official journal of the American Thyroid Association

[ISO-abbreviation] Thyroid

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.

A 56-year-old married female presented in May 1998 with a 5-month history of xanthelasma of the eyelids, followed 4 months later by two enlarged lymph nodes of the left side of the neck and three of the left axilla.

In July 1998, computed tomography (CT) scans of the chest and abdomen with contrast medium showed pretracheal, bilateral axillary, right retrochural, paracaval, aortocaval, and para-aortic lymph node enlargement.

These findings were suggestive of lymphoma.

One cervical and two left axillary lymph nodes were excised.

They revealed total replacement of the nodular architecture by a diffuse proliferation of mature lymphoid cells having small nuclei and a crumbled chromatin pattern, and very rare mitosis.

It was concluded from the lymph node biopsies that these changes were typical of non-Hodgkin's lymphoma, diffuse and small cell type, of low-grade malignancy.

The bone marrow picture was consistent with diffuse, well-differentiated non-Hodgkin's lymphoma, developing into chronic lymphocytic leukemia (CLL).

Endoscopy showed antral-type gastric mucosa exhibiting mild chronic gastritis.

Skin biopsy from a fresh lesion on the back showed a diffuse inflammatory cell infiltrate with collections of histiocytic cells.

The blood picture also showed monoclonal IgG paraprotein (3170 mg/dL) of the kappa light chain type.

The patient was treated by the oncologist for her lymphoma, and was given Cytoxan, prednisolone, endoxan, Leukeran, and melphalan.

She also responded to Leukeran at a dose of 5 mg daily for 5 days every month for 6 months, and showed regression in the size of the lymph nodes.

[MeSH-major] Granuloma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / complications. Necrobiotic Disorders / pathology. Paraproteinemias / etiology. Xanthomatosis / pathology

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

Genetic Alliance. consumer health - Xanthogranuloma.

Hazardous Substances Data Bank. MELPHALAN .

Hazardous Substances Data Bank. CHLORAMBUCIL .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16533236.001).

[ISSN] 0011-9059

[Journal-full-title] International journal of dermatology

[ISO-abbreviation] Int. J. Dermatol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO.

In this study, thirteen infants with diagnosis of MAS and PPHN were first treated with conventional respiratory support.

Then between 2 and 22h of life they were randomized either to bolus surfactant treatment (n=6) or surfactant lung lavage (SLL, n=7) treatment.

The results showed that infants treated with SLL had significant improvements in oxygenation, decreases in MAP and A-a gradients.

In conclusion these data show no advantage of SLL therapy over bolus surfactant treatment in infants with MAS complicated by PPHN.

Hazardous Substances Data Bank. NITRIC OXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19057612.001).

[ISSN] 1476-5543

[Journal-full-title] Journal of perinatology : official journal of the California Perinatal Association

[ISO-abbreviation] J Perinatol

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Pulmonary Surfactants; 31C4KY9ESH / Nitric Oxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

She underwent multiple laparotomies in which histological sections of the entire small intestine could be obtained.

A more detailed immunohistochemical analysis using neuronal (PGP, enolase), glial (S100), and lymphocytic (LCA) antibodies demonstrated a nearly complete neuronal loss.

[MeSH-major] Enteric Nervous System / pathology. Enteric Nervous System / virology. Herpes Zoster / complications. Intestinal Diseases / etiology. Intestine, Small / innervation

[MeSH-minor] Child, Preschool. Female. Humans. Ileus / etiology. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

MedlinePlus Health Information. consumer health - Shingles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16516611.001).

[ISSN] 1531-5037

[Journal-full-title] Journal of pediatric surgery

[ISO-abbreviation] J. Pediatr. Surg.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.

There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL).

This agent has a high degree of activity against a variety of tumor cell lines.

Clinically, bendamustine has demonstrated activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle cell lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]

[Cites] Anticancer Drugs. 2005 Sep;16(8):871-7 [16096436.001]

[Cites] J Clin Oncol. 2009 Feb 10;27(5):812-26 [19103723.001]

[Cites] Ther Clin Risk Manag. 2008 Aug;4(4):727-32 [19209254.001]

[Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]

[Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]

[Cites] Biochim Biophys Acta. 1972 Dec 22;287(3):386-9 [4629776.001]

[Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):12-4 [12170426.001]

[Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]

[Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]

[Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]

[Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12 [16402269.001]

[Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]

[Cites] Cancer Chemother Pharmacol. 2007 May;59(6):759-70 [16957931.001]

[Cites] Anticancer Drugs. 2007 Jun;18(5):587-95 [17414628.001]

[Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]

[Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]

[Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]

[Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53 [17653574.001]

[Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S13-7 [18282361.001]

[Cites] Blood. 2008 Jul 15;112(2):330-9 [18451308.001]

[Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):227-34 [18719942.001]

[Cites] Blood. 2008 Oct 1;112(7):2596-7 [18809766.001]

[Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]

[Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]

[Cites] Pharmazie. 1985 Nov;40(11):782-4 [4095129.001]

[Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9 [12458340.001]

[Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):4-11 [12170425.001]

[Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]

[Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12 [16088404.001]

[Cites] J Clin Oncol. 2005 Oct 20;23(30):7565-73 [16186600.001]

[Cites] J Clin Oncol. 2005 Nov 1;23(31):7985-93 [16204016.001]

[Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):99-104 [16292542.001]

[Cites] Br J Cancer. 2007 Jun 4;96(11):1692-8 [17486132.001]

[Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]

[Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]

[Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]

[Cites] Leukemia. 2002 Oct;16(10):2096-105 [12357363.001]

[Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]

[Cites] Leuk Lymphoma. 2004 Sep;45(9):1821-7 [15223642.001]

[Cites] Leuk Lymphoma. 2004 May;45(5):911-3 [15291348.001]

[Cites] Leuk Lymphoma. 2004 Dec;45(12):2445-9 [15621757.001]

[Cites] Haematologica. 2001 May;86(5):485-93 [11410411.001]

[Cites] Anticancer Drugs. 2001 Oct;12(9):725-9 [11593053.001]

[Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]

[Cites] Leuk Lymphoma. 2002 Feb;43(2):327-31 [11999564.001]

[Cites] J Cancer Res Clin Oncol. 2002 May;128(5):271-8 [12029443.001]

[Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]

(PMID = 21188134.001).

[ISSN] 1179-1322

[Journal-full-title] Cancer management and research

[ISO-abbreviation] Cancer Manag Res

[Language] eng

[Publication-type] Journal Article

[Publication-country] New Zealand

[Other-IDs] NLM/ PMC3004665

[Keywords] NOTNLM ; Treanda / alkylating agent / bendamustine / chronic lymphocytic lymphoma / indolent non-Hodgkin lymphoma

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for diagnosis and classification of non Hodgkin lymphoma.

AIMS AND OBJECTIVES: In this present study we have evaluated the feasibility of sub-classification of non-Hodgkin's lymphoma (NHL) cases according to World Health Organization's (WHO) classification on fine needle aspiration cytology (FNAC) material along with flow cytometric immunotyping (FCI) as an adjunct.

Both cytologic findings and FCI data were interpreted together to diagnose and sub-classify NHL according to WHO classification.

The cases were classified on FNAC as predominant small cells (12), mixed small and large cells (5) and large cells (26).

In five cases a suggestion of NHL was offered on FNAC material and these cases were labeled as NHL not otherwise specified (NHL-NOS).

With the help of combined FCI and FNAC, it was possible to sub-classify 38 cases of NHL (79%) according to WHO classification.

Combined FNAC and FCI data helped to diagnose 9 cases of small lymphocytic lymphoma (SLL), 2 cases of mantle cell lymphoma (MCL), 4 cases of follicular lymphoma (FL), 17 cases of diffuse large B lymphoma (DLBL) and 6 cases of lymphoblastic lymphoma.

Histopathology diagnosis was available in 31 cases of NHL out of which there were 14 recurrent and 17 cases of primary NHL.

Out of 15 DLBL cases diagnosed on FCI and FNAC, histology confirmed 14 cases and one of these cases was diagnosed as Burkitt's lymphoma on histology.

Cases of FL (4), SLL (3) and MCL (2) were well correlated with histopathology.

Histology diagnosis was given as DLBL (1), SLL (1), anaplastic large cell lymphoma (1) and FL transformed into large cell NHL (1).

Considering histopathology as gold standard, diagnostic specificity of combined FNAC and FCI was 100% (31/31) and sensitivity in sub-classification was 83.8% (26/31).

CONCLUSION: FNAC combined with FCI may be helpful in accurately sub-classifying NHL according to WHO classification.

Many of the subtypes of NHL such as FL and MCL which were previously recognized as a pure morphologic entity can be diagnosed by combined use of FNAC and FCI.

Other ancillary investigations such as chromosomal changes, cell proliferation markers etc. may be helpful in this aspect.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Diagn Cytopathol. 1998 Oct;19(4):274-8 [9784991.001]

[Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]

[Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]

[Cites] J Clin Pathol. 2000 Jun;53(6):451-7 [10911803.001]

[Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1792-9 [11100059.001]

[Cites] Diagn Cytopathol. 2001 Apr;24(4):229-32 [11285616.001]

[Cites] Diagn Cytopathol. 2002 Apr;26(4):251-6 [11933272.001]

[Cites] Diagn Cytopathol. 2002 Dec;27(6):340-2 [12451563.001]

[Cites] Diagn Cytopathol. 2003 Apr;28(4):191-5 [12672094.001]

[Cites] Diagn Cytopathol. 1992;8(5):551-2 [1396035.001]

[Cites] Cancer. 2005 Dec 25;105(6):432-42 [16222688.001]

[Cites] Diagn Cytopathol. 1996 Nov;15(4):352-7 [8982596.001]

[Cites] Blood. 1996 Sep 1;88(5):1771-9 [8781434.001]

[Cites] Cancer. 1990 Jan 1;65(1):72-7 [2293872.001]

[Cites] Cytopathology. 2006 Oct;17(5):275-87 [16961657.001]

[Cites] Acta Cytol. 1990 May-Jun;34(3):329-36 [2343687.001]

[Cites] Acta Cytol. 1984 May-Jun;28(3):337-45 [6587711.001]

[Cites] Diagn Cytopathol. 1995 May;12(3):201-7 [7621714.001]

[Cites] Acta Cytol. 1993 Sep-Oct;37(5):745-6 [8362592.001]

[Cites] Histopathology. 1994 Dec;25(6):517-36 [7698729.001]

(PMID = 17069647.001).

[ISSN] 1742-6413

[Journal-full-title] CytoJournal

[ISO-abbreviation] Cytojournal

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC1634871

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma.

Follicular lymphoma (FL) is a neoplasm originating from germinal centre cells, corresponding to 25-40% of non-Hodgkin's lymphomas.

Transformation into diffuse large B cell lymphoma (DLBCL) occurs in about one-third of cases.

CD5 is expressed in B-chronic lymphoid leukaemia/small lymphocytic lymphoma and mantle cell lymphoma, but can rarely be expressed in conjunction with CD10 in well-documented cases of FL.

In this report one case of grade 1 FL is described, which transformed into a DLBCL 6 months after initial diagnosis, with both tumours expressing CD5.

[MeSH-major] Antigens, CD5 / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

[MeSH-minor] Adult. Antigens, Neoplasm / metabolism. Disease Progression. Female. Humans

Genetic Alliance. consumer health - Follicular Lymphoma.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):1-11 [10937042.001]

[Cites] Am J Clin Pathol. 2005 Aug;124(2):182-90 [16040287.001]

[Cites] Am J Clin Pathol. 2000 Dec;114(6):912-21 [11338480.001]

[Cites] Arch Pathol Lab Med. 2001 Jul;125(7):951-3 [11419985.001]

[Cites] Am J Clin Pathol. 2002 Feb;117(2):291-300 [11863226.001]

[Cites] Am J Clin Pathol. 2002 Oct;118(4):589-98 [12375647.001]

[Cites] Am J Clin Pathol. 2003 Feb;119(2):218-30 [12579992.001]

[Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2105-11 [15313456.001]

[Cites] J Clin Pathol. 1992 Nov;45(11):1018-22 [1280654.001]

[Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]

[Cites] Br J Haematol. 1996 Sep;94(4):676-84 [8826892.001]

[Cites] J Clin Pathol. 1997 Jan;50(1):16-21 [9059349.001]

[Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]

[Cites] Mol Pathol. 1998 Dec;51(6):333-8 [10193514.001]

[Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]

(PMID = 17513519.001).

[ISSN] 0021-9746

[Journal-full-title] Journal of clinical pathology

[ISO-abbreviation] J. Clin. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD5; 0 / Antigens, Neoplasm

[Other-IDs] NLM/ PMC1994527

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed.

The boxer breed is at high risk for developing lymphoma and, in contrast to the general canine population, is predisposed to the T-cell variant of the disease.

The purpose of this study was to more accurately classify lymphoma in this breed.

Clinical, cytomorphologic and immunophenotypic data were examined in 43 boxers with lymphoma.

Lymphomas were classified as multicentric (n=29), mediastinal (n=6) and intestinal (n=8).

Of the 40 immunophenotyped samples, 34 (85%) were T-cell, 5 (12.5%) were B-cell and 1 was a non-B-cell non-T-cell lymphoma.

Immunophenotypic subtyping was done on prospectively collected T-cell lymphoma samples (n=22) to differentiate CD4 (helper) from CD8 (cytotoxic) T-cell origin as well as to determine the T-cell receptor (TCR) expression (TCRalphabeta vs. TCRdeltagamma).

Cytomorphologic analysis was done on the same 22 samples using the World Health Organization (WHO) classification scheme.

According to this scheme, 17/22 samples were classified as lymphoblastic, 2/22 as large cell peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), 2/22 as large granular lymphoma (LGL) high-grade and 1/22 as small lymphocytic.

The results of this study indicate that lymphoma in the boxer breed is a disease comprised predominantly of TCRalphabeta+, CD4+ (helper) T-cells with lymphoblastic (high-grade) morphology.

[MeSH-major] Dog Diseases / classification. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / veterinary

[MeSH-minor] Animals. Antigens, CD4 / blood. Antigens, CD4 / immunology. Antigens, CD8 / blood. Antigens, CD8 / immunology. Biopsy, Fine-Needle / veterinary. Dogs. Female. Genetic Predisposition to Disease. Immunohistochemistry / veterinary. Immunophenotyping / veterinary. Kaplan-Meier Estimate. Male. Prospective Studies. Receptors, Antigen, T-Cell, alpha-beta / blood. Receptors, Antigen, T-Cell, alpha-beta / immunology. Receptors, Antigen, T-Cell, gamma-delta / blood. Receptors, Antigen, T-Cell, gamma-delta / immunology. Retrospective Studies

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18579219.001).

[ISSN] 0165-2427

[Journal-full-title] Veterinary immunology and immunopathology

[ISO-abbreviation] Vet. Immunol. Immunopathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gender differences in serum leptin concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and type-2 diabetic mothers.

To investigate gender differences, if any, in leptin concentrations from umbilical cord blood of new born infants of mothers with type 2 diabetes mellitus (DM), gestational diabetes mellitus (GDM), and Non diabetic (ND) at delivery.

Serum leptin concentrations were measured in 105 newborns (53 males and 52 females in the three groups).

Pearson correlation coefficient was used to explore the relationship between serum leptin concentrations and anthropometric measures of the fetus and their mother.

Both Serum leptin level and serum C-peptide was measured by chemiluminescence based ELISA.

The median range of leptin concentration in cord blood was ND group: Male [13.91 (3.22 - 47.63)], Female [16.88 (2 - 43.65)]; GDM group: Male [32 (7 - 76.00)], Female [36.73 (4.80 - 81.20)]; DM group: Male [20.90 (2 -76.00)], Female [32 {2.58 - 80.67)].

Cord serum leptin levels correlated with birth weight(r=0.587, p=0.0001), ponderal index (PI) (r=.319, p=0.024)of the babies and body mass index (BMI) (r=-0.299, p=0.035) of their mothers but did not correlate with gestational age, cord serum C-peptide concentration or placental weight at delivery.

Leptin concentrations were higher in the female fetus in comparison to the male fetus.

We found that there are very strong associations between cord leptin concentrations at delivery and birth weight, ponderal index of the baby, body mass index of the mothers with Type 2 DM.

We also found that high leptin levels could represent an important feedback modulator of substrate supply and subsequently for adipose tissue status during late gestation or adipose tissue is the major determinant of circulating leptin levels.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biochem Biophys Res Commun. 1995 Sep 25;214(3):1260-7 [7575539.001]

[Cites] Eur J Endocrinol. 2001 Jul;145(1):53-8 [11415852.001]

[Cites] Science. 1995 Jul 28;269(5223):546-9 [7624778.001]

[Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]

[Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]

[Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]

[Cites] Nat Med. 1996 Sep;2(9):949-50 [8782440.001]

[Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7 [8784109.001]

[Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]

[Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1293-300 [9100610.001]

[Cites] J Clin Endocrinol Metab. 1997 May;82(5):1642-4 [9141565.001]

[Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):2849-55 [9284709.001]

[Cites] Eur J Endocrinol. 1997 Dec;137(6):655-8 [9437232.001]

[Cites] Diabetes. 1998 May;47(5):847-50 [9588462.001]

[Cites] Science. 1995 Jul 28;269(5223):540-3 [7624776.001]

(PMID = 20336197.001).

[ISSN] 1998-3832

[Journal-full-title] International journal of diabetes in developing countries

[ISO-abbreviation] Int J Diabetes Dev Ctries

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC2839129

[Keywords] NOTNLM ; Newborn infants / Serum leptin / Type 2 Diabetic / Umbilical cord blood / gestational diabetes mellitus / non diabetic

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Histological variety of floral variant of follicular lymphoma.

To further clarify the histopathological findings of the floral variant of follicular lymphoma (FVFL), we studied 13 Japanese cases.

Two histological subtypes of neoplastic follicles of FVFL have been described: (i) A macrogerminal center pattern where the mantle zone lymphocytes were invaginated into the neoplastic germinal center, often reminiscent of a floral design. (ii) A microgerminal center pattern where the massive invasion of mantle zone lymphocytes resulted in almost complete breakage of the neoplastic follicles.

In the former pattern, the neoplastic germinal center usually contained large clusters of tumor cells, whereas in the latter, small clusters of up to 20 tumor cells or isolated tumor cells were observed in the neoplastic germinal centers.

Moreover, occasional tumor cells showed a lymphocytic and/or histiocytic Reed-Sternberg cell (L&H cells)-like morphology.

The overall histological findings of the macrogerminal center are similar to those of florid progressive transformation of germinal center (PTGC), whilst the microgerminal center pattern is similar to that of nodular lymphocyte-predominant Hodgkin lymphoma.

Initially, the differential diagnosis between FVFL and florid PTGC was emphasized.

However, the present study indicates that nodal marginal zone B-cell lymphoma possessing floral follicles and nodular lymphocyte-predominant Hodgkin lymphoma should be added to the differential diagnosis of FVFL.

The germinal center B-cell nature of FVFL is most clearly recognizable by immunohistochemistry, though histological appearance alone may cause some diagnostic problems.

[MeSH-major] Lymph Nodes / pathology. Lymphoma, Follicular / pathology

[MeSH-minor] Adult. Aged. Antigens, CD / analysis. Diagnosis, Differential. Female. Germinal Center / pathology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Oligonucleotides. RNA, Viral / analysis

Genetic Alliance. consumer health - Follicular Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16948815.001).

[ISSN] 0903-4641

[Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

[ISO-abbreviation] APMIS

[Language] eng

[Publication-type] Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Antigens, CD; 0 / Oligonucleotides; 0 / RNA, Viral

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The objective is to test the effect of the LAD on pulmonary histopathology in juvenile piglets with acute lung injury caused by saline lung lavage (SLL) followed by intermittent mandatory ventilation (IMV).

Three- to 4-wk-old piglets were randomized to no intervention (control group), SLL alone (SLL group), SLL + IMV (IMV group), or SLL + IMV + LAD (LAD group) (n = 6 per group).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Chest. 1989 Oct;96(4):849-51 [2676391.001]

[Cites] Early Hum Dev. 2008 Nov;84(11):709-16 [18930613.001]

[Cites] J Thorac Cardiovasc Surg. 1993 May;105(5):823-32 [7683735.001]

[Cites] J Thorac Cardiovasc Surg. 1994 Mar;107(3):838-48; discussion 848-9 [8127113.001]

[Cites] J Pediatr. 1994 Jul;125(1):104-10 [7517446.001]

[Cites] Perfusion. 1994;9(4):265-9 [7981464.001]

[Cites] J Paediatr Child Health. 1995 Apr;31(2):105-11 [7794609.001]

[Cites] Anesthesiology. 1995 Oct;83(4):710-20 [7574050.001]

[Cites] J Pediatr. 1996 Jan;128(1):109-17 [8551400.001]

[Cites] ASAIO J. 1994 Jul-Sep;40(3):M728-31 [8555610.001]

[Cites] Lancet. 1996 Jul 13;348(9020):75-82 [8676720.001]

[Cites] Pediatr Pulmonol. 1996 Oct;22(4):263-70 [8905887.001]

[Cites] J Paediatr Child Health. 1997 Jun;33(3):202-8 [9259293.001]

[Cites] Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1058-65 [9351603.001]

[Cites] ASAIO J. 1997 Sep-Oct;43(5):M821-4 [9360161.001]

[Cites] Pediatr Pulmonol Suppl. 1997;16:51 [9443195.001]

[Cites] Ann Thorac Surg. 2000 Feb;69(2):351-6 [10735662.001]

[Cites] N Engl J Med. 2000 May 4;342(18):1301-8 [10793162.001]

[Cites] Intensive Care Med. 2000 Sep;26(9):1334-42 [11089761.001]

[Cites] J Thorac Cardiovasc Surg. 2001 Mar;121(3):542-51 [11241090.001]

[Cites] Biol Neonate. 2001 Jul;80(1):74-80 [11474154.001]

[Cites] Ann Thorac Surg. 2001 Sep;72(3):899-904 [11570380.001]

[Cites] ASAIO J. 2001 Sep-Oct;47(5):486-91 [11575823.001]

[Cites] J Pediatr. 2001 Oct;139(4):478-86 [11598592.001]

[Cites] Am J Respir Crit Care Med. 2001 Oct 1;164(7):1154-60 [11673202.001]

[Cites] Pediatr Res. 2002 Sep;52(3):387-92 [12193673.001]

[Cites] Ann Thorac Surg. 2002 Oct;74(4):1011-6; discussion 1017-8 [12400738.001]

[Cites] Pediatr Res. 2003 Feb;53(2):245-53 [12538782.001]

[Cites] Crit Care Med. 2003 Mar;31(3):885-92 [12627001.001]

[Cites] Eur Respir J Suppl. 2003 Aug;42:2s-9s [12945994.001]

[Cites] Respir Physiol Neurobiol. 2004 Jan 15;139(2):167-77 [15123000.001]

[Cites] Anesthesiology. 2004 Sep;101(3):722-8 [15329597.001]

[Cites] Minerva Pediatr. 2004 Aug;56(4):373-80 [15457135.001]

[Cites] JAMA. 1986 Aug 15;256(7):881-6 [3090285.001]

[Cites] Am J Respir Crit Care Med. 1998 Jan;157(1):294-323 [9445314.001]

[Cites] Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1332-47 [9563759.001]

[Cites] J Pharmacol Toxicol Methods. 1998 Aug;40(2):101-7 [10100499.001]

[Cites] Clin Chest Med. 2006 Dec;27(4):601-13; abstract viii [17085249.001]

[Cites] Clin Physiol Funct Imaging. 2007 Mar;27(2):67-90 [17309528.001]

[Cites] J Pediatr. 2007 Jul;151(1):10-5 [17586183.001]

[Cites] Neonatology. 2007;92(1):19-25 [17596733.001]

[Cites] Intensive Care Med. 2007 Aug;33(8):1423-33 [17563879.001]

[Cites] Am J Respir Crit Care Med. 2007 Sep 15;176(6):575-81 [17641159.001]

[Cites] Crit Care Med. 2008 Jan;36(1):183-7 [18090370.001]

[Cites] Int J Mol Med. 2008 Apr;21(4):513-9 [18360698.001]

[Cites] J Perinatol. 2008 May;28 Suppl 1:S47-56 [18446178.001]

[Cites] Ann Thorac Surg. 2008 Aug;86(2):410-7; discussion 417 [18640306.001]

[Cites] BMC Pulm Med. 2008;8:10 [18625067.001]

[Cites] J Pediatr Surg. 1992 Jan;27(1):40-3 [1552442.001]

(PMID = 19687779.001).

[ISSN] 1530-0447

[Journal-full-title] Pediatric research

[ISO-abbreviation] Pediatr. Res.

[Language] ENG

[Grant] United States / NICHD NIH HHS / HD / HD046513-02; United States / NICHD NIH HHS / HD / K08 HD046513; United States / NHLBI NIH HHS / HL / R01 HL092906; United States / NICHD NIH HHS / HD / K08 HD046513-02

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ NIHMS149422; NLM/ PMC2796292

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature.

Diagnosis of two distinct malignant entities existing concurrently and at the same location (synchronous malignancy) by fine- needle aspiration (FNA) is unusual but may occur.

Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) in particular is associated with an increased incidence of secondary tumor, likely due to associated immunodeficiency.

Co-occurrence of some carcinomas such as squamous cell carcinoma (SCC), may show especially aggressive behavior.

A 57-year-old Caucasian male presented with recurrent upper extremity lymphedema and diffuse lymphadenopathy of the axillary and cervical regions.

FNA of a large cervical lymph node was diagnostic for both atypical lymphocytic proliferation and SCC.

Flow cytometric analysis showed the atypical lymphocytic proliferation to be positive for CD5, CD23, CD19, CD20, HLA-DR, CD38, and the population was kappa light chain restricted.

These cells were negative for CD-10 and FMC-7 antigens, suggesting a phenotype of B-cell SLL/CLL.

We report a rare occurrence of metastatic SCC to a lymph node infiltrated by SLL/CLL.

The diagnosis was achieved by a combination of cytomorphologic examination of FNA smears, immunohistochemical staining of cell block material, and flow cytometry on the sample obtained by FNA.

To the best of our knowledge, only three cases of SCC metastasis to SLL/CLL diagnosed by FNA have been reported in the English literature.

[MeSH-major] Carcinoma, Squamous Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Neoplasms, Multiple Primary / diagnosis. Oropharyngeal Neoplasms / pathology

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 18973126.001).

[ISSN] 1097-0339

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Number-of-references] 16

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury.

OBJECTIVES: To measure serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury (SCI) and to investigate possible correlations between these serum levels and various factors, such as body mass index (BMI), age, injury level, and duration of injury.

MAIN OUTCOME MEASURES: Serum levels of adiponectin, ghrelin, and leptin and BMI.

RESULTS: Serum leptin levels in subjects with SCI (mean, 7.0+/-0.5 mg/mL) [corrected] were significantly higher than those in able-bodied controls (mean, 4.7+/-0.6 mg/mL) [corrected] (P<.01).

The group with tetraplegia had higher serum leptin levels than the group with paraplegia, but this did not reach a statistically significant level (8.2+/-1.1 ng/mL vs 6.4+/-0.5 mg/mL [corrected] P=.097).

There were significant differences in serum leptin levels among the 3 groups by 1-way analysis of variance (P=.008).

Serum adiponectin levels in subjects with SCI (7.1+/-0.5 mg/mL) [corrected] were higher than those in able-bodied controls (5.6+/-0.5 mg/mL) [corrected] but this was not statistically significant (P=.08).

In contrast, serum levels of ghrelin in subjects with SCI (302.0+/-17.5 pg/mL) were similar to those in the controls (264.0+/-27.0 pg/mL) (P=.24).

Serum leptin levels correlated positively with BMI (SCI, r=.698, P<.001; controls, r=.782, P<.001), whereas serum adiponectin (SCI, r=-.527, P<.001; controls, r=-.315, P=.057) and ghrelin (SCI, r=-.368, P<.001; controls, r=-.447, P=.006) levels correlated negatively with the BMI in both subjects with SCI and controls.

CONCLUSIONS: Men with SCI have significantly higher serum leptin levels than able-bodied controls, and serum leptin levels correlated with the degree of neurologic deficit.

Men with SCI had a tendency toward higher serum adiponectin level than able-bodied controls.

Serum levels of ghrelin in men with SCI were similar to those of controls.

[MeSH-major] Leptin / blood. Peptide Hormones / blood. Spinal Cord Injuries / blood

MedlinePlus Health Information. consumer health - Spinal Cord Injuries.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Arch Phys Med Rehabil. 2007 May;88(5):688

(PMID = 16213239.001).

[ISSN] 0003-9993

[Journal-full-title] Archives of physical medicine and rehabilitation

[ISO-abbreviation] Arch Phys Med Rehabil

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Ghrelin; 0 / Leptin; 0 / Peptide Hormones

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] FISH detection of t(14;18) in follicular lymphoma on Papanicolaou-stained archival cytology slides.

BACKGROUND: The t(14;18)(q32;q21) translocation is present in about 85% of follicular lymphomas (FL) and can be identified using fluorescence in situ hybridization (FISH).

The authors proposed FISH for FL using Papanicolaou-stained archival cytology material as a practical ancillary technique for diagnosing FL.

METHODS: Cases included 35 FL, 6 small lymphocytic lymphomas/chronic lymphocytic leukemias (SLL/CLL), 4 mantle cell lymphomas (MCL), 4 marginal zone lymphomas (MZL), 1 lymphoplasmacytic lymphoma (LPL), and 10 reactive lymphoid tissues (RLT).

This series shows a sensitivity of 81% and specificity of 100% for detecting the t(14;18) translocation as a diagnostic tool in FL.

[MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Lymphoma, Follicular / pathology. Translocation, Genetic

[MeSH-minor] Biopsy, Fine-Needle. Humans. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoid Tissue / pathology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Staining and Labeling

Genetic Alliance. consumer health - Follicular Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16671111.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum leptin levels, hormone levels, and hot flashes in midlife women.

OBJECTIVE: To examine the associations between serum leptin levels, sex steroid hormone levels, and hot flashes in normal weight and obese midlife women.

MAIN OUTCOME MEASURE(S): Serum leptin and sex steroid hormone levels.

RESULT(S): Correlation and regression models were performed to examine associations between leptin levels, hormone levels, and hot flashes.

Leptin levels were associated with BMI, with "ever experiencing hot flashes" (questionnaire), with hot flashes within the last 30 days, and with duration of hot flashes (>1 year, P=.03).

Leptin was positively correlated with testosterone, free testosterone index, and free estrogen index and inversely associated with levels of sex hormone-binding globulin.

In women with a body mass index>or=30 kg/m2, leptin levels no longer correlated with testosterone levels.

CONCLUSION(S): Serum leptin levels are associated with the occurrence and duration of hot flashes in midlife women; however, no correlation was found between leptin and serum estradiol.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

[Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2354-8 [7629229.001]

[Cites] Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):772-80 [8456878.001]

[Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]

[Cites] Maturitas. 1996 Apr;23(3):301-5 [8794424.001]

[Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):318-21 [8989281.001]

[Cites] Endocrinology. 1997 Feb;138(2):847-50 [9003026.001]

[Cites] Br J Obstet Gynaecol. 1997 Aug;104(8):923-33 [9255084.001]

[Cites] Endocrinology. 1998 Feb;139(2):551-8 [9449624.001]

[Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):453-9 [9467557.001]

[Cites] Clin Exp Obstet Gynecol. 1997;24(3):163-6 [9478308.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2541-6 [9482922.001]

[Cites] Menopause. 1998 Spring;5(1):43-51 [9689194.001]

[Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):428-34 [10022396.001]

[Cites] Ginekol Pol. 1999 Jan;70(1):1-7 [10349800.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7047-52 [10359836.001]

[Cites] Endocrine. 1999 Feb;10(1):19-23 [10403567.001]

[Cites] Semin Reprod Med. 2005 May;23(2):117-25 [15852197.001]

[Cites] Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E166-71 [15741239.001]

[Cites] Am J Obstet Gynecol. 2005 Aug;193(2):347-51 [16098853.001]

[Cites] Am J Obstet Gynecol. 2005 Oct;193(4):1353-60 [16202725.001]

[Cites] Alcohol Alcohol. 2005 Nov-Dec;40(6):563-8 [16087658.001]

[Cites] Maturitas. 2006 Jan 20;53(2):217-25 [15913927.001]

[Cites] Maturitas. 2006 Jan 20;53(2):133-43 [16368467.001]

[Cites] Obstet Gynecol. 1994 Jul;84(1):29-34 [8008318.001]

[Cites] Maturitas. 2006 Jun 20;54(3):260-9 [16423474.001]

[Cites] Clin Endocrinol (Oxf). 2006 Jul;65(1):125-31 [16817831.001]

[Cites] Climacteric. 2007 Feb;10(1):27-37 [17364602.001]

[Cites] Fertil Steril. 2007 Jun;87(6):1483-6 [17276432.001]

[Cites] Obesity (Silver Spring). 2007 Sep;15(9):2217-24 [17890489.001]

[Cites] Am J Epidemiol. 2008 Jan 1;167(1):78-85 [17881385.001]

[Cites] Maturitas. 2008 Feb 20;59(2):149-57 [18280066.001]

[Cites] Fertil Steril. 2008 Oct;90(4):1161-8 [18304548.001]

[Cites] Int J Biometeorol. 1999 Nov;43(3):99-109 [10639901.001]

[Cites] J Womens Health Gend Based Med. 2001 Jan-Feb;10(1):67-76 [11224946.001]

[Cites] Am J Hum Biol. 2001 Jul-Aug;13(4):453-64 [11400216.001]

[Cites] Obstet Gynecol. 2001 Sep;98(3):391-7 [11530118.001]

[Cites] Maturitas. 2002 Jan 30;41(1):69-77 [11809345.001]

[Cites] J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1417-29 [11837495.001]

[Cites] Atherosclerosis. 2002 Apr;161(2):455-62 [11888531.001]

[Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4522-7 [12364429.001]

[Cites] Obstet Gynecol. 2003 Feb;101(2):264-72 [12576249.001]

[Cites] Am J Epidemiol. 2004 Jun 15;159(12):1189-99 [15191936.001]

[Cites] Endocrinology. 2004 Jul;145(7):3115-21 [15059958.001]

[Cites] J Gen Intern Med. 2004 Jul;19(7):740-6 [15209587.001]

[Cites] Clin Endocrinol (Oxf). 1985 Mar;22(3):293-312 [3884189.001]

[Cites] Ann Clin Biochem. 1985 Sep;22 ( Pt 5):489-97 [4062218.001]

[Cites] J Clin Endocrinol Metab. 1987 Apr;64(4):723-9 [3818901.001]

[Cites] Int J Obes. 1989;13(1):1-9 [2703288.001]

[Cites] Metabolism. 1991 Jan;40(1):101-4 [1984562.001]

[Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]

(PMID = 19476935.001).

[ISSN] 1556-5653

[Journal-full-title] Fertility and sterility

[ISO-abbreviation] Fertil. Steril.

[Language] ENG

[Grant] United States / NIA NIH HHS / AG / R01 AG018400-02; United States / NIA NIH HHS / AG / AG18400; United States / NIA NIH HHS / AG / R01 AG018400-03; United States / NIA NIH HHS / AG / R01 AG018400-05A2; United States / NIA NIH HHS / AG / R01 AG018400-01A1; United States / NIA NIH HHS / AG / R01 AG018400-06; United States / NIA NIH HHS / AG / R01 AG018400; United States / NIA NIH HHS / AG / R01 AG018400-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Leptin

[Other-IDs] NLM/ NIHMS109122; NLM/ PMC3939020

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.

The pathogenetic relationship of marginal zone B-cell lymphoma (MALT lymphoma) of the gastrointestinal (GI) tract and eventually co-existing aggressive B-cell lymphoma and primary aggressive B-cell lymphoma remains to be elucidated.

The RNA of laser-microdissected cells was isolated and amplified from small and/or large cell compartments of eight MALT lymphomas (small cell lymphoma, SCL), 14 GI diffuse large B-cell lymphomas (large cell lymphoma, LCL), and ten GI B-cell lymphomas with composite small and large cell compartments (ComL) and expression analyses were performed using cDNA arrays.

Hierarchical cluster analysis clearly separated SCL and LCL and the small and large cell compartments of ComL.

Likewise, cluster analysis with all samples of SCL, LCL, and ComL yielded two main 'small cell' and 'large cell' branches.

Furthermore, 60 genes were differentially expressed between SCL and LCL, and 82 genes between the small and large cell components of ComL; 26 genes were discriminators in both settings.

Use of the profiles of ComL as training sets for class prediction resulted in 95% accuracy for the classification of SCL and LCL.

Collectively, the data strongly suggest that both secondary and primary aggressive B-cell lymphomas of the GI tract are blastic marginal zone lymphomas.

[MeSH-major] Gastrointestinal Neoplasms / genetics. Gene Expression Profiling. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Oligonucleotide Array Sequence Analysis. Transcription, Genetic

[MeSH-minor] Genetic Markers. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - B-Cell Lymphomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

(PMID = 17152084.001).

[ISSN] 0022-3417

[Journal-full-title] The Journal of pathology

[ISO-abbreviation] J. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Genetic Markers

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does leptin predict incident hypertension in older adults?

OBJECTIVE: Leptin is associated with blood pressure (BP) in experimental and cross-sectional studies, but only one previous prospective study of middle-aged men has reported the association between leptin and incident hypertension.

We examined the association of leptin levels with incident hypertension in a population-based study of older men and women.

POPULATION: Participants were 602 community-dwelling older adults with normal baseline BP levels who attended a research clinic visit between 1984 and 1987 and again 4.4 years later (mean age was 66.2 +/- 11.4; 60.6% were men; mean body mass index (BMI) 24.9 +/- 3.4 kg/m(2)).

Leptin was measured by radioimmunoassay.

Baseline serum leptin levels were higher in participants who developed hypertension compared to persistent normotensives [median (25th-75th range)] [8.8(5-16) vs 7(4-11) ng/ml, P = 0.002].

In logistic regression models, leptin (log-transformed) predicted incident hypertension before and after adjustments for baseline age, BMI, systolic BP, total cholesterol, medications, and previous cardiovascular disease (OR 1.75 95% CI 1.17-2.61, P = 0.006).

CONCLUSION: Higher leptin levels were independently associated with increased odds of incident hypertension in older adults.

MedlinePlus Health Information. consumer health - High Blood Pressure.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hypertension. 2009 Mar;53(3):473-9 [19204185.001]

[Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3922-6 [18682500.001]

[Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44 [19174500.001]

[Cites] Am J Hypertens. 2009 May;22(5):577-80 [19229195.001]

[Cites] Hypertension. 2009 Jun;53(6):965-72 [19398660.001]

[Cites] J Vasc Res. 2009;46(6):609-17 [19571581.001]

[Cites] Diabetes Care. 2000 Jan;23(1):57-63 [10857969.001]

[Cites] Hypertens Res. 2000 Jul;23(4):303-10 [10912765.001]

[Cites] Int J Obes Relat Metab Disord. 2001 Jan;25(1):121-5 [11244467.001]

[Cites] Metabolism. 2001 Mar;50(3):325-9 [11230786.001]

[Cites] Clin Exp Hypertens. 2001 May;23(4):357-68 [11349826.001]

[Cites] J Neuroendocrinol. 2001 Oct;13(10):913-21 [11679060.001]

[Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]

[Cites] Obes Res. 2003 Jan;11(1):160-6 [12529499.001]

[Cites] JAMA. 2003 May 21;289(19):2560-72 [12748199.001]

[Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31 [14557461.001]

[Cites] Nephron. 1976;16(1):31-41 [1244564.001]

[Cites] Prev Med. 1976 Jun;5(2):207-15 [935073.001]

[Cites] Am J Epidemiol. 1980 Jun;111(6):705-12 [7386445.001]

[Cites] Hypertension. 1997 Sep;30(3 Pt 2):619-23 [9322991.001]

[Cites] Hypertension. 1998 Jan;31(1 Pt 2):409-14 [9453337.001]

[Cites] Eur J Pharmacol. 2005 Aug 22;518(2-3):175-81 [16054621.001]

[Cites] J Hypertens. 2006 May;24(5):789-801 [16612235.001]

[Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):532-41 [17118991.001]

[Cites] Am J Clin Nutr. 2009 Mar;89(3):991S-997S [19176740.001]

(PMID = 20148909.001).

[ISSN] 1365-2265

[Journal-full-title] Clinical endocrinology

[ISO-abbreviation] Clin. Endocrinol. (Oxf)

[Language] ENG

[Grant] United States / NIA NIH HHS / AG / AG028507-03; United States / NIDDK NIH HHS / DK / R01 DK031801-15; United States / NIA NIH HHS / AG / R01 AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-13S1; United States / NIA NIH HHS / AG / AG007181-13S1; United States / NIA NIH HHS / AG / R01 AG028507-02; United States / NIA NIH HHS / AG / R01 AG007181; United States / NIA NIH HHS / AG / AG07181; United States / NIDDK NIH HHS / DK / R01 DK031801; United States / NIA NIH HHS / AG / AG007181-13; United States / NIA NIH HHS / AG / R01 AG007181-13; United States / NIDDK NIH HHS / DK / R01 DK031801-16; United States / NIDDK NIH HHS / DK / DK31801; United States / NIA NIH HHS / AG / R01 AG028507-03; United States / NIA NIH HHS / AG / AG028507-02; United States / NIA NIH HHS / AG / AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-14; United States / NIA NIH HHS / AG / R37 AG007181; United States / NIA NIH HHS / AG / R01 AG028507; United States / NIA NIH HHS / AG / AG028507

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Leptin

[Other-IDs] NLM/ NIHMS175266; NLM/ PMC2891171

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.

OBJECTIVE: The adipocytokine leptin regulates weight centrally and participates in the regulation of the immune and inflammatory responses.

In the present study we investigated whether inflammation, obesity or both of these characteristics are potential determinants of circulating leptin concentrations in a group of RA patients on periodical treatment with the TNF-alpha-blocker-infliximab due to severe disease.

We also assessed whether the infusion of infliximab may alter circulating leptin concentrations in patients with severe RA.

Serum leptin levels were determined immediately prior to and after infliximab infusion.

RESULTS: There was a positive correlation between body mass index of RA patients and baseline serum level of leptin (rho=0.665, p<0.001).

Apart from a significant correlation with VCAM-1 (rho=0.349, p=0.04), no significant correlations between baseline leptin levels and the age at the time of the study or at the onset of the disease, disease duration, ESR and CRP levels, DAS28, lipids, insulin sensitivity, adhesion molecules, resistin, adiponectin, ghrelin or the cumulative prednisone dose at the time of the study were found.

Leptin levels did not change upon infliximab infusion (p=0.48).

CONCLUSION: In RA patients on TNF-alpha blocker treatment, circulating leptin levels are unrelated to disease activity but constitute a manifestation of adiposity.

The beneficial effect of anti-TNF-alpha therapy on cardiovascular mortality in RA does not seem to be mediated by reduction in serum levels of leptin.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Arthritis, Rheumatoid / blood. Arthritis, Rheumatoid / drug therapy. Leptin / blood. Obesity / blood. Tumor Necrosis Factor-alpha / antagonists & inhibitors

Genetic Alliance. consumer health - Arthritis.

Genetic Alliance. consumer health - Rheumatoid arthritis.

MedlinePlus Health Information. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

Hazardous Substances Data Bank. Infliximab .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19473561.001).

[ISSN] 0392-856X

[Journal-full-title] Clinical and experimental rheumatology

[ISO-abbreviation] Clin. Exp. Rheumatol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; B72HH48FLU / Infliximab

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In response to HFD, body weight, fat pad weights, adipocyte size, and serum leptin levels increased significantly more in SHR.1N than SHR.

Microarray gene expression profiles [Affymetrix, 15,923 genes and expressed sequence tags (ESTs)] showed that multiple genes of molecular pathways involved in lipogenesis were downregulated to a similar level in both strains, whereas genes involved in fatty acid oxidation and energy dissipation were upregulated less in SHR.1N than SHR.

MedlinePlus Health Information. consumer health - Dietary Fats.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Hypertension. 2000 Jul;36(1):14-9 [10904006.001]

[Cites] Nature. 2008 Aug 21;454(7207):961-7 [18719582.001]

[Cites] Cell. 2001 Sep 7;106(5):563-73 [11551504.001]

[Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]

[Cites] Diabetes. 2002 Jun;51(6):1876-83 [12031976.001]

[Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]

[Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]

[Cites] J Biol Chem. 2003 Apr 4;278(14):11888-96 [12529376.001]

[Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]

[Cites] Hypertension. 2003 May;41(5):1047-55 [12654711.001]

[Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]

[Cites] Physiol Rev. 2004 Jan;84(1):277-359 [14715917.001]

[Cites] Science. 2004 May 28;304(5675):1301-5 [15166374.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jul;287(1):R112-9 [15001430.001]

[Cites] Nature. 2004 Sep 9;431(7005):200-5 [15306821.001]

[Cites] Cell. 1982 May;29(1):53-60 [7105184.001]

[Cites] Biochem J. 1988 Feb 1;249(3):765-9 [3355496.001]

[Cites] Mol Endocrinol. 1988 May;2(5):395-403 [2901666.001]

[Cites] J Hypertens. 1989 Mar;7(3):217-21 [2708818.001]

[Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]

[Cites] J Clin Invest. 1995 Jul;96(1):158-62 [7615786.001]

[Cites] J Clin Invest. 1995 Dec;96(6):2914-23 [8675663.001]

[Cites] Diabetes. 1997 Sep;46(9):1468-72 [9287048.001]

[Cites] Eur J Clin Invest. 1998 Jan;28(1):59-66 [9502188.001]

[Cites] J Clin Invest. 1998 Jul 15;102(2):412-20 [9664083.001]

[Cites] J Clin Invest. 2004 Dec;114(12):1752-61 [15599400.001]

[Cites] J Biol Chem. 2005 Apr 22;280(16):15493-6 [15746100.001]

[Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):31-4 [15936931.001]

[Cites] Biol Cell. 2005 Jul;97(7):479-86 [15966863.001]

[Cites] FASEB J. 2005 Sep;19(11):1567-9 [16009704.001]

[Cites] Am J Hypertens. 2005 Oct;18(10):1271-5 [16202847.001]

[Cites] Annu Rev Cell Dev Biol. 2005;21:247-69 [16212495.001]

[Cites] Obes Res. 2005 Dec;13(12):2122-31 [16421346.001]

[Cites] Curr Opin Nephrol Hypertens. 2006 Mar;15(2):173-8 [16481885.001]

[Cites] Cell Metab. 2006 Mar;3(3):223-9 [16517409.001]

[Cites] Exp Hematol. 2006 Aug;34(8):1106-14 [16863918.001]

[Cites] Biochem J. 2006 Sep 1;398(2):153-68 [16898874.001]

[Cites] Nature. 2006 Dec 14;444(7121):847-53 [17167472.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4401-6 [17360536.001]

[Cites] Int J Obes (Lond). 2007 Jun;31(6):1004-13 [17130847.001]

[Cites] J Lipid Res. 2007 Dec;48(12):2751-61 [17872589.001]

[Cites] FEBS Lett. 2008 Jan 9;582(1):117-31 [18037376.001]

[Cites] Mol Endocrinol. 2008 May;22(5):1023-31 [18202144.001]

[Cites] Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E356-67 [18492779.001]

[Cites] Curr Hypertens Rep. 1999 Feb-Mar;1(1):42-50 [10981041.001]

(PMID = 19383622.001).

[ISSN] 1531-2267

[Journal-full-title] Physiological genomics

[ISO-abbreviation] Physiol. Genomics

[Language] ENG

[Grant] United States / Howard Hughes Medical Institute / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin

[Other-IDs] NLM/ PMC2696153

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The relationship between leptin level and oxidative status parameters in hemodialysis patients.

Both serum leptin level and oxidative stress are increased in hemodialysis (HD) patients.

In the present study, we aimed to investigate whether there is association between oxidative status and leptin level in HD patients.

Serum leptin level, total peroxide (TP) level, total antioxidant capacity (TAC), and oxidative stress index (OSI) were determined.

Serum leptin level, TP level, and OSI were significantly higher in HD patients than controls (all P < 0.001) while TAC was lower (P < 0.001).

In HD patients, serum leptin level was significantly correlated with TP level and OSI (r = 0.372, P < 0.001 and r = 0.409, P < 0.001, respectively).

The correlation of serum leptin level with TP level and OSI remained statistically significant after adjusting for age, gender, and body-fat percentage (r = 0.446, P < 0.001 and r = 0.463, P < 0.001, respectively).

Hyperleptinemia seems to be associated with increased oxidative stress in HD patients, and this association may provide better understanding about the disorders related to either elevated serum leptin levels and/or increased oxidative stress in HD patients.

[MeSH-major] Leptin / blood. Oxidative Stress. Renal Dialysis

MedlinePlus Health Information. consumer health - Dialysis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19178446.001).

[ISSN] 1525-1594

[Journal-full-title] Artificial organs

[ISO-abbreviation] Artif Organs

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antioxidants; 0 / Leptin; 0 / Peroxides

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum leptin level in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling.

Since leptin was suggested to be involved in bone remodeling, its possible involvement in fracture formation/prevention was evaluated, by determination of serum leptin level in geriatric population with hip fracture, and evaluation the relationships with biochemical parameters of bone remodeling.

Serum leptin level of this total population distributed between 1 and 134ng/ml.

40% of patients were in the normal range of our laboratory (10-40ng/ml), 40% had decreased leptin level (<10ng/ml) and 20% had higher leptin level (>40ng/ml).

No correlation was detected between serum leptin level and vitamin D-25(OH)D3, which was under normal range in 60% of the patients.

Leptin also did not correlate to ICTP level, which was high in 80% of the patients, suggesting an extensive bone resorption in this population.

Evaluation of leptin level in female versus male suggests that leptin level is higher in females than males also in this age (28.4ng/ml vs. 14.4ng/ml, p<0.001).

The higher leptin levels in women was accompanied by higher serum levels of glucose, albumin, Ca, cholesterol, Na and FT4.

Comparison of 50 patients with the lowest leptin levels (mean of 3.4ng/ml) to 50 patients with highest leptin levels (mean of 34ng/ml), did not indicate differences in both 25(OH)D3 and ICTP between these two populations in spite of the highly significant difference in leptin levels.

The high range of serum leptin concentration in these geriatric patients with hip fracture of both sexes, and the absence of any correlation between leptin and the tested parameters of bone resorption and Ca metabolism, teleopeptide type I collagen (ICTP) and 25(OH)D3, does not support a direct massive involvement of serum leptin in hip fracture of the very old population.

[MeSH-major] Bone Remodeling / physiology. Hip Fractures / blood. Leptin / blood

[MeSH-minor] Aged. Aged, 80 and over. Biomarkers / blood. Calcifediol / blood. Case-Control Studies. Cohort Studies. Collagen Type I. Dihydroxycholecalciferols / blood. Female. Humans. Male. Peptide Fragments / blood. Peptides. Procollagen / blood. Sex Distribution

MedlinePlus Health Information. consumer health - Hip Injuries and Disorders.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18359113.001).

[ISSN] 1872-6976

[Journal-full-title] Archives of gerontology and geriatrics

[ISO-abbreviation] Arch Gerontol Geriatr

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Dihydroxycholecalciferols; 0 / Leptin; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; P6YZ13C99Q / Calcifediol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.

Although numerous options are available for patients with recurrent low-grade non-Hodgkin's lymphoma (NHL), responses are rarely durable.

We previously conducted a phase I trial of fludarabine and paclitaxel in the treatment of recurrent low-grade lymphoma.

Twenty-two (78%) patients had grade 1 or 2 follicular lymphoma, and six patients (21%) had small lymphocytic lymphoma.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

[MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Rate. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUDARABINE .

Hazardous Substances Data Bank. TAXOL .

Hazardous Substances Data Bank. VIDARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17064994.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article

[Publication-country] England

[Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; P88XT4IS4D / Paclitaxel

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma.

Allergy/atopy has been suggested to protect against non-Hodgkin lymphoma (NHL) and specific IgE levels are decreased in patients with NHL.

We speculated that all immunoglobulin subclass levels might be downregulated in NHL and examined levels of IgM, IgD, IgA, IgE, IgG and IgG(4) in 200 NHL patients and 200 age- and sex-matched controls.

Patients with B-cell NHL of many types had consistently lower median immunoglobulin subclass levels than controls.

In every subclass except IgD, about 10-15% of B-cell NHL patients had absolute levels below the 2.5 percentile of controls.

Subclass levels correlated with each other and many patients had more than one significantly low level.

Levels were lowest for IgG(4) and IgE.

Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had especially low total IgE levels.

In other B-cell NHL types, total IgE levels were decreased to a similar extent as other immunoglobulin subclasses.

In conclusion, low IgE levels are only part of a more generalized loss of immunoglobulins of all subtypes in a wide variety of B-cell NHL types.

Low immunoglobulin levels appear to be a consequence of B-cell NHL presence, and we speculate about molecular mechanisms that could reduce all immunoglobulin subclasses in B-cell NHL.

[MeSH-major] Immunoglobulins / classification

[MeSH-minor] Adolescent. Adult. Aged. Antigens, CD80 / blood. Female. Humans. Immunoglobulin E / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19235925.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD80; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 37341-29-0 / Immunoglobulin E

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In addition, the use of small molecules against specific cell surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders.

Nevertheless, additional studies are needed to determine where and when such management fits into a therapeutic regimen for any given disorder, whether upfront or as salvage therapy, alone or in combination with chemotherapy (concurrent or sequential).

[MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / immunology. Multiple Myeloma / drug therapy. Multiple Myeloma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Radioimmunotherapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15855891.001).

[ISSN] 1073-2748

[Journal-full-title] Cancer control : journal of the Moffitt Cancer Center

[ISO-abbreviation] Cancer Control

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Immunologic Factors

[Number-of-references] 129

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

FACC1KO mice showed prenatal growth retardation; after weaning, however, their weight gain was comparable to that of wild-type (WT) mice on a normal diet.

In addition, there was about a 30% decrease in serum insulin-like growth factor I (IGF1), and while the serum leptin level was decreased by about 50%, it did not counteract the osteopenic effects of IGF1 on the bone.

Fatty acid analyses of mutant bone lipids revealed relatively higher levels of C18:2n-6 and C18:3n-3 and lower levels of their elongation C20 homologs than that of WT cohorts, leading to lower levels of C20 homologs and bone development.

MedlinePlus Health Information. consumer health - Growth Disorders.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 1964 Feb;239:375-80 [14169133.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 [10359843.001]

[Cites] Expert Opin Ther Targets. 2005 Apr;9(2):267-81 [15934915.001]

[Cites] Cell Metab. 2005 Feb;1(2):107-19 [16054052.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12011-6 [16103361.001]

[Cites] Cell Mol Life Sci. 2005 Aug;62(16):1784-803 [15968460.001]

[Cites] Mol Cell Biol. 2006 Feb;26(3):1063-76 [16428458.001]

[Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8552-7 [16717184.001]

[Cites] J Bone Miner Res. 2006 Sep;21(9):1350-8 [16939393.001]

[Cites] Transgenic Res. 2006 Oct;15(5):647-53 [16952017.001]

[Cites] Endocrinology. 2006 Oct;147(10):4753-61 [16857753.001]

[Cites] Bioorg Med Chem Lett. 2007 Mar 15;17(6):1803-7 [17234407.001]

[Cites] Gastroenterology. 2007 May;132(6):2103-15 [17498506.001]

[Cites] Cell. 2007 Aug 10;130(3):456-69 [17693256.001]

[Cites] Nat Med. 2008 Mar;14(3):299-305 [18297084.001]

[Cites] Cell. 2000 Jan 21;100(2):197-207 [10660043.001]

[Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]

[Cites] Endocr Rev. 2000 Aug;21(4):393-411 [10950158.001]

[Cites] Endocrinology. 2000 Dec;141(12):4436-41 [11108252.001]

[Cites] Dev Biol. 2001 Jan 1;229(1):141-62 [11133160.001]

[Cites] Prog Lipid Res. 2001 Jan-Mar;40(1-2):125-48 [11137570.001]

[Cites] Trends Endocrinol Metab. 2000 Oct;11(8):327-32 [10996528.001]

[Cites] Science. 2001 Mar 30;291(5513):2613-6 [11283375.001]

[Cites] Biochem J. 2001 Aug 15;358(Pt 1):127-35 [11485560.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):138-43 [11756679.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7515-20 [12810950.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7 [14660788.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3258-63 [14978271.001]

[Cites] Methods Enzymol. 1975;35:59-65 [235706.001]

[Cites] J Biol Chem. 1983 Sep 25;258(18):11074-81 [6136512.001]

[Cites] Annu Rev Biochem. 1983;52:537-79 [6137188.001]

[Cites] J Biol Chem. 1985 May 25;260(10):6318-23 [2860106.001]

[Cites] J Biol Chem. 1988 May 5;263(13):6447-53 [2896193.001]

[Cites] Cell. 1993 Oct 8;75(1):73-82 [8402902.001]

[Cites] Genes Dev. 1993 Dec;7(12B):2609-17 [8276243.001]

[Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]

[Cites] Gene. 1995 Mar 10;154(2):271-5 [7890176.001]

[Cites] Brain Res Dev Brain Res. 1997 Feb 20;98(2):197-203 [9051261.001]

[Cites] Annu Rev Nutr. 1997;17:77-99 [9240920.001]

[Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]

[Cites] Genes Dev. 1999 Apr 15;13(8):1025-36 [10215629.001]

[Cites] J Nutr Biochem. 2004 Nov;15(11):651-6 [15590268.001]

(PMID = 19805143.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / R01 GM063115; United States / NIGMS NIH HHS / GM / GM-63115

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Primers; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / aminoglycoside N1-acetyltransferase; EC 6.4.1.2 / Acetyl-CoA Carboxylase

[Other-IDs] NLM/ PMC2762677

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lymphoma--emerging realities in sub-Saharan Africa.

Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.

Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.

Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.

This was followed by 32 months for those with mantle cell (n=7), splenic (n=2) and extranodal marginal cell (n=11), 24 months for T-cell lymphomas (n=24), 20 months for diffuse large B-cell variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).

The remaining 36 patients had to be excluded because numbers were too small for statistical analysis or unreliable staging.

In contrast gender, staging by Rye or Rai classification, retroviral infection and prior treatment with radiotherapy were without effect.

Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).

Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).

Outcome argues in favour of patient management by a multidisciplinary team implicit in which are standardised protocols for diagnosis, staging and treatment.

Under these circumstances the well recognized centre effect applies when results approximate those from first world reference centres.

[MeSH-major] Lymphoma

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2010. Published by Elsevier Ltd.

(PMID = 20149748.001).

[ISSN] 1473-0502

[Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

[ISO-abbreviation] Transfus. Apher. Sci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.

BACKGROUND: Solar radiation has been identified as a principal factor for the causation of melanoma, whereas changing lifestyle patterns associated with obesity and diabetes might also contribute to the increasing incidence of the malignancy.

No study has investigated the role of leptin, a hormone whose levels increase in obesity and which has also been related to cancer.

Anthropometrical measures were also recorded and blood samples were obtained for determination of serum leptin levels.

RESULTS: An excess melanoma risk was observed for sun sensitive individuals and those with high circulating levels of leptin (OR: 1.56, 95% confidence interval 1.07-2.28, P = 0.02), after controlling for obesity indices, diabetes mellitus and education.

CONCLUSIONS: Melanoma risk was found to be positively associated with serum leptin levels and inversely with healthy lifestyle factors.

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17925285.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical and biochemical parameters in relation to serum leptin levels in South Indian children and adolescents.

OBJECTIVE: To investigate the relationship between serum leptin and lipid profile in South Indian School children and adolescents, and to evaluate the role of serum leptin in obese, overweight and congenital heart diseased children and adolescents; in South Indian population and its correlation with anthropometric and biochemical parameters.

Anthropometric variables, lipid profile, fasting serum glucose were analyzed by autoanalyser and serum leptin by ELISA.

RESULTS: Serum leptin levels were significantly elevated in obese and overweight children than in control children (36.88+/-18.60ng/mL, 20.64+/-11.18ng/mL vs 7.97+/-2.79ng/mL; p value <0.001), and decreased in congenital heart diseased children than in control children (6.20+/-4.23 ng/mL vs 7.97+/-2.79ng/mL; p value <0.005).

CONCLUSIONS: This study provides a good relationship between serum leptin levels and anthropometric and biochemical parameters, such as total cholesterol, triglycerides and LDL-cholesterol.

We observed negative correlation between serum leptin and fasting glucose levels and HDL-cholesterol levels were found to be non-significant among the groups.

Further studies with large sample size are needed to ascertain the relationship between serum leptin and lipid profile in different groups of children and adolescents.

[MeSH-major] Heart Defects, Congenital / blood. Leptin / blood. Lipids / blood. Obesity / blood. Overweight / blood

MedlinePlus Health Information. consumer health - Congenital Heart Defects.

MedlinePlus Health Information. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Obesity in Children.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Invest. 1997 Aug 15;100(4):808-13 [9259579.001]

[Cites] J Clin Invest. 2000 May;105(9):1243-52 [10791999.001]

[Cites] Obes Res. 2003 Apr;11(4):532-40 [12690082.001]

[Cites] Eur J Clin Nutr. 2007 Jun;61(6):719-26 [17164827.001]

[Cites] Ann Intern Med. 1997 Jan 1;126(1):26-31 [8992920.001]

[Cites] Int J Cardiol. 2003 Nov;92(1):93-7 [14602223.001]

[Cites] Eur J Epidemiol. 2001;17(10):911-6 [12188009.001]

[Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]

[Cites] J Intern Med. 1999 Oct;246(4):409-18 [10583712.001]

[Cites] Obes Res. 2005 Aug;13(8):1476-84 [16129731.001]

[Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2148-52 [9215286.001]

[Cites] Indian Pediatr. 2007 Apr;44(4):257-62 [17468520.001]

[Cites] Pediatrics. 2005 Apr;115(4):e500-3 [15741351.001]

[Cites] Indian J Pediatr. 2006 Jul;73(7):593-6 [16877853.001]

[Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]

(PMID = 20401706.001).

[ISSN] 0973-7693

[Journal-full-title] Indian journal of pediatrics

[ISO-abbreviation] Indian J Pediatr

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Biomarkers; 0 / Leptin; 0 / Lipids

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women.

OBJECTIVE: To compare the changes in body composition and in leptin levels in postmenopausal women receiving hormone therapy (HT) or tibolone.

MAIN OUTCOME MEASURE(S): Anthropometric indices, leptin levels, tissue fat percentage, total fat, and lean mass measurements were performed at baseline and after 6 months.

RESULT(S): The serum leptin levels were in strong correlation with the total fat percentage and total fat mass at baseline.

Untreated women had weight gain and a gradual decrease in leptin levels.

Women receiving HT had significantly increased leptin levels.

Women in the tibolone group, however, had a significant decrease in leptin levels accompanied by decreased total fat mass, fat percentage, and increased total lean mass.

The changes in leptin levels were more pronounced in lean women.

CONCLUSION(S): Postmenopausal women tend to gain weight accompanied with a reduction in leptin concentrations.

Hormone therapy administration increases leptin levels while maintaining body weight and body fat distribution, whereas tibolone use decreases leptin levels, total fat percentage, and total fat mass.

[MeSH-major] Adiposity / drug effects. Estrogen Replacement Therapy. Estrogens, Conjugated (USP) / therapeutic use. Leptin / blood. Medroxyprogesterone Acetate / therapeutic use. Norpregnenes / therapeutic use. Postmenopause. Weight Gain / drug effects

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18249383.001).

[ISSN] 1556-5653

[Journal-full-title] Fertility and sterility

[ISO-abbreviation] Fertil. Steril.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Estrogens, Conjugated (USP); 0 / Leptin; 0 / Norpregnenes; C2QI4IOI2G / Medroxyprogesterone Acetate; FF9X0205V2 / tibolone

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells.

Serum leptin levels are often elevated in obese people.

Leptin has been reported to act as a mitogenic agent and promote renal cancer cell proliferation, whereas the detailed mechanisms still remain to be elucidated.

The purpose of this study is to investigate the proliferation and mobility effects in leptin-treated Caki-2 renal cell carcinoma and analyze the alterations of leptin-inducible STAT3 pathways and mitogenic signaling ERK pathways.

Our results indicate the constitutive expression of leptin receptor could not be upregulated upon the stimulation of leptin in Caki-2 cells.

Leptin increases the proliferation and mobility capabilities of Caki-2 cells via upregulating the expression of both phosphor-ERK and phosphor-STAT3 and these two pathways could be partially abolished by inhibition of the activation of JAK-STAT3 and completely abrogated by inhibition of ERK1/2 pathways.

Our results also suggest that mitogenic actions of leptin are not the consequence of altered its receptor expression; whereas the cellular proliferation appears to be working through the cross-talking of JAK-STAT3 and ERK1/2 pathways in renal cell carcinoma caki-2 cells.

[MeSH-major] Carcinoma, Renal Cell / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation. Janus Kinase 1 / metabolism. Leptin / metabolism. STAT3 Transcription Factor / metabolism

[MeSH-minor] Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Humans. Kidney Neoplasms / metabolism. MAP Kinase Signaling System. Obesity / metabolism. Protein Kinase C / metabolism. Signal Transduction

Genetic Alliance. consumer health - Renal cell carcinoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18787400.001).

[ISSN] 1555-8576

[Journal-full-title] Cancer biology & therapy

[ISO-abbreviation] Cancer Biol. Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Leptin; 0 / STAT3 Transcription Factor; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].

OBJECTIVE: To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem cell transplantation (HSCT).

PTLD was diagnosed on the basis of finding diffuse hyperplasia characterized by invasion of other organ structure with disorganization of the nodal structure in lymph nodes.

If pathological investigation was not possible, PTLD was diagnosed by the presence of fever, lymph node enlargement and/or EBV viral load, which could not be explained by other causes.

The morphology of biopsy appeared as small B-lymphocytic lymphoma; there was no response to chemotherapy and the patients died.

One patient recovered by reducing immunosuppressive drug therapy combined with MP and one patient recovered by reducing immunosuppressive/antivirus therapy and donor lymphocyte infusion.

[MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / etiology

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18478915.001).

[ISSN] 0578-1426

[Journal-full-title] Zhonghua nei ke za zhi

[ISO-abbreviation] Zhonghua Nei Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / HLA Antigens

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.

BACKGROUND: A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined.

Serum leptin levels were within the range predicted by the elevated fat mass in these subjects.

Their clinical features were less severe than those of subjects with congenital leptin deficiency.

Circulating levels of leptin were not disproportionately elevated, suggesting that serum leptin cannot be used as a marker for leptin-receptor deficiency.

Congenital leptin-receptor deficiency should be considered in the differential diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism.

[MeSH-major] Metabolism, Inborn Errors / diagnosis. Metabolism, Inborn Errors / genetics. Obesity / genetics. Receptors, Cell Surface / deficiency. Receptors, Cell Surface / genetics

[MeSH-minor] Adult. Age of Onset. Basal Metabolism. Body Composition. Child. Diagnosis, Differential. Female. Genotype. Humans. Hyperphagia / blood. Hyperphagia / complications. Hyperphagia / genetics. Hypogonadism / blood. Hypogonadism / complications. Hypogonadism / genetics. Immunologic Deficiency Syndromes / blood. Immunologic Deficiency Syndromes / complications. Immunologic Deficiency Syndromes / genetics. Leptin / blood. Lymphocyte Count. Male. Mutation. Pedigree. Phenotype. Receptors, Leptin

Genetic Alliance. consumer health - Leptin receptor deficiency.

Genetics Home Reference. consumer health - leptin receptor deficiency.

Genetics Home Reference. consumer health - LEPR gene.

MedlinePlus Health Information. consumer health - Obesity.

MedlinePlus Health Information. consumer health - Obesity in Children.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

SciCrunch. OMIM: Data: Gene Annotation .

SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2007 Massachusetts Medical Society.

[Cites] Diabetes. 2000 Aug;49(8):1347-52 [10923636.001]

[Cites] Clin Endocrinol (Oxf). 2006 Jun;64(6):667-71 [16712669.001]

[Cites] Int J Obes Relat Metab Disord. 2002 May;26(5):640-6 [12032747.001]

[Cites] Obes Rev. 2001 Feb;2(1):29-36 [12119634.001]

[Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]

[Cites] N Engl J Med. 2003 Mar 20;348(12):1085-95 [12646665.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6 [15070752.001]

[Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):4821-6 [15472169.001]

[Cites] Am J Clin Nutr. 1979 Mar;32(3):607-29 [420153.001]

[Cites] Am J Clin Nutr. 1982 May;35(5 Suppl):1169-75 [7081099.001]

[Cites] Am J Clin Nutr. 1991 Dec;54(6):963-9 [1957828.001]

[Cites] Eur J Clin Nutr. 1993 Oct;47(10):724-34 [8269887.001]

[Cites] Diabet Med. 1995 Jan;12(1):30-5 [7712700.001]

[Cites] Arch Dis Child. 1995 Jul;73(1):25-9 [7639544.001]

[Cites] J Pediatr. 1995 Oct;127(4):571-7 [7562278.001]

[Cites] Biochem Biophys Res Commun. 1997 Apr 7;233(1):248-52 [9144432.001]

[Cites] Nature. 1997 Jun 26;387(6636):903-8 [9202122.001]

[Cites] Nat Genet. 1997 Jul;16(3):303-6 [9207799.001]

[Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]

[Cites] Nature. 1998 Mar 26;392(6674):398-401 [9537324.001]

[Cites] Am J Physiol. 1998 Apr;274(4 Pt 2):R985-90 [9575960.001]

[Cites] Nat Genet. 1998 Jun;19(2):155-7 [9620771.001]

[Cites] Nature. 1998 Aug 27;394(6696):897-901 [9732873.001]

[Cites] Baillieres Clin Endocrinol Metab. 1998 Jul;12(2):297-314 [10083898.001]

[Cites] N Engl J Med. 1999 Sep 16;341(12):879-84 [10486419.001]

[Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3686-95 [10523015.001]

[Cites] Annu Rev Med. 2005;56:443-58 [15660521.001]

[Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1849-55 [15598687.001]

[Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1871-87 [15598688.001]

[Cites] Nature. 2001 Nov 1;414(6859):34-5 [11689931.001]

(PMID = 17229951.001).

[ISSN] 1533-4406

[Journal-full-title] The New England journal of medicine

[ISO-abbreviation] N. Engl. J. Med.

[Language] eng

[Grant] Italy / Telethon / / GJT04008; United Kingdom / Wellcome Trust / / 077016; United Kingdom / Wellcome Trust / / 068086; United Kingdom / Medical Research Council / / G0502115; United Kingdom / Wellcome Trust / / 067457; United Kingdom / Wellcome Trust / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human

[Other-IDs] NLM/ PMC2670197; NLM/ UKMS4351